Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma …

Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …

Rationale: Tezepelumab reduced exacerbations in patients with severe, uncontrolled
asthma across a range of baseline blood eosinophil counts and fractional exhaled nitric …

Background Patients with severe, uncontrolled asthma experience frequent exacerbations
and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY …

Background Patients with severe, uncontrolled asthma have a significant unmet need for
new treatments that have broader effects on airway inflammation, and that provide greater …

Background Tezepelumab is a human monoclonal antibody that blocks the activity of the
epithelial cytokine thymic stromal lymphopoietin. The efficacy, safety and oral corticosteroid …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR …

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the
pathogenesis of asthma. Tezepelumab (tezepelumab-ekko; TEZSPIRE™) is a first-in-class …

Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine. In phase 2b and 3 studies …

Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …